SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, has closed on its previously announced public offering. According to the announcement, the offering was comprised of 3,846,154 shares of its common stock (or prefunded warrants in … Continue reading →

Scinai Immunotherapeutics (NASDAQ: SCNI) today announced the execution of a formal amendment to its finance contract with the European Investment Bank (“EIB”). According to the announcement, the amendment extends the maturity date of the contract by four years from Dec. … Continue reading →

Multi-strategy operating company Diamond Lake Minerals (OTC: DLMI) CEO Brian J. Esposito highlighted the company’s rapid early growth trajectory during a new interview with the Proactive Investors webcast, pointing out Diamond Lake’s market capitalization jump from “around a million dollars” … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting additional positive interim results from its human pilot study evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, available commercially as Rybelsus(R). According to … Continue reading →

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal pest populations, has launched its Evolve(TM) Soft Bait product at Ace Hardware franchise locations in California; the franchise also began selling SenesTech’s Isolate(TM) bait system. According to the announcement, this … Continue reading →

SuperCom (NASDAQ: SPCB), a global leading provider of traditional and digital identity solutions offering advanced safety, identification, and security solutions to governments, just released its financial and operating results for the third quarter of the 2023 financial year (“Q3 2023”). … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced positive interim results from a human pilot study currently underway evaluating DehydraTECH(TM) technology for the oral delivery of the glucagon-like peptide-1 (“GLP-1”) drug semaglutide, which is … Continue reading →

Safety Shot (NASDAQ: SHOT), a wellness and functional beverage company, has begun a double-blind, placebo-controlled clinical trial designed to study and evaluate the effects of its flagship product, Safety Shot, on blood and breath alcohol levels. According to the announcement, … Continue reading →

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that the company and Rapid Response Defense Systems (“RRDS”) have filed responses for final ruling and compliance by the U.S. Customs and Border Protection (“CBP”) application for Mullen’s … Continue reading →

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has closed its previously announced public offering. The offering was comprised of 5,384,615 shares of common stock (or common stock equivalents in lieu thereof) and warrants; the … Continue reading →

D-Wave Quantum (NYSE: QBTS), a leader in commercial quantum computing systems, software, and services, recently announced financial results for its fiscal third quarter, which ended September 30, 2023. D-Wave CEO Dr. Alan Baratz believes this is a pivotal moment in … Continue reading →

Renovaro BioSciences (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, was featured in a recent Proactive interview. Mark Dybul, CEO of Renovaro, joined host Steve Darling to talk … Continue reading →